Finanzen von Flora Growth Corp (FLGC)FLGCFlora Growth Corp

Flora Growth Corp (FLGC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Commercial & Wholesale, accounting for 66.8% of total sales, equivalent to $9.88M. Other significant revenue streams include House of Brands and Eliminations. Understanding this composition is critical for investors evaluating how FLGC navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Flora Growth Corp maintains a gross margin of 3.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -33.50%, while the net margin is -37.21%. These profitability ratios, combined with a Return on Equity (ROE) of -46.03%, provide a clear picture of how effectively FLGC converts its operational activities into shareholder value.

In the context of the broader market, FLGC competes directly with industry leaders such as ASBP and YCBD. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, FLGC's gross margin of 3.36% stands against ASBP's -47.68% and YCBD's 53.29%. Such benchmarking helps identify whether Flora Growth Corp is trading at a premium or discount relative to its financial performance.

Latest quarter: 2025/Q3.

Revenue: 9.75M, up 34.68% YoY (clear top-line growth).

Profitability: Net income still negative at -6.66M (improved YoY but still a sizable loss).

EPS: -9.05, worse YoY (-17.95%), indicating per-share performance deterioration.

Margins: Gross margin 3.36%, down ~50% YoY—this is the key red flag because it limits the benefit of revenue growth and makes the business highly sensitive to costs/pricing.